Evidence map›Paper›PMID 40610845›Full record

ArticleJournal of neuro-oncology2025

Cystic glioblastoma IDH-wildtype: genetic alterations and outcomes.

Jose Torres, Bethany E Bundrant, Antonio Dono, Pavel S Pichardo-Rojas, Sigmund Hsu, Mark Amsbaugh, Jay-Jiguang Zhu, Angel I Blanco, Roy F Riascos, Nitin Tandon and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jose Torres *Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Bethany E Bundrant *Internal Medicine Department, Baylor College of Medicine, Houston, TX, USA.
Antonio DonoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Pavel S Pichardo-RojasVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Sigmund HsuVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Mark AmsbaughVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Jay-Jiguang ZhuVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Angel I BlancoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Roy F RiascosMemorial Hermann Hospital-TMC, Houston, TX, 77030, USA.
Nitin TandonVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
Leomar Y BallesterDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yoshua Esquenazi *Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA. Yoshua.EsquenaziLevy@uth.tmc.edu.ORCID http://orcid.org/0000-0002-9757-1453

Funding

National Cancer Institute of the National Institutes of Health, United States K08CA241651
6 · The paper itself

Abstract

purposeIn the past decade, studies have reclassified infiltrating glioblastomas (GBM) IDH-wildtype utilizing molecular and phenotypic features. Cystic GBMs are one such phenotypic subtype whose genetic and clinical characteristics remain incompletely understood. The goal of this study was to genetically characterize cystic GBMs and examine patient outcomes as compared to non-cystic GBMs.

methodsRetrospective analysis of GBM IDH-wildtype with pre-operative and post-operative MRI and comprehensive next-generation sequencing were performed with evaluation of 205 genes. Tumors were evaluated by their cystic characteristics. Benjamini-Hochberg's false discovery rate (BH-FDR) was performed for multiple comparison adjustments. Univariable and multivariable analysis for survival was performed.

results176 GBM IDH-WT patients met the inclusion criteria. Of these, 17 patients were identified as having a cystic component. Compared to non-cystic GBMs, cystic GBMs had a higher incidence of mutation in PDGFRA (41.2% vs. 16.4%, p = 0.021), RB1 (35.3% vs 11.9%, p = 0.019), and KIT (35.3% vs 10.7%, p = 0.012), and a lower incidence of mutation in CDKN2A/B (41.2% vs 69.2%, p = 0.029). No difference in progression-free survival (6.87 vs 7.83 months. p = 0.541) or overall survival (19.5 vs 18.2 months, p = 0.243) was identified between patients with cystic versus non-cystic GBM.

conclusionsCystic GBMs were found to have lower frequencies of CDKN2A/B alterations and higher frequencies of PDGFRA, KIT, and RB1 alterations as compared to non-cystic GBMs. No statistically significant differences in PFS or OS were identified.

Indexed as

Biomarkers, TumorBrain NeoplasmsCystsGlioblastomaIsocitrate DehydrogenaseMutationAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival RateBiomarkers, TumorIsocitrate Dehydrogenase4q12CysticGBMImaging characteristicsRANORB

Identifiers

PMID40610845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.